PwPepwise

Cetrorelix

Sex & Libido

a.k.a. Cetrotide

GnRH antagonist

Cetrorelix is a synthetic peptide that works by blocking the body's gonadotropin-releasing hormone (GnRH) receptor, which rapidly.

§Dosing at a glance

5 protocols · from the research
What it's forDoseHow oftenHowFor how long
Multiple-dose protocol (IVF/ICSI — most widely studied)0.25 mgOnce dailySubcutaneousInjected just under the skin, into the fat layer.—
Single-dose protocol (IVF — alternative regimen)3 mg—SubcutaneousInjected just under the skin, into the fat layer.—
Flexible low-dose protocol0.25 mgDaily——
IUI cycles0.25 mg/day—SubcutaneousInjected just under the skin, into the fat layer.—
PCOS patients0.25 mgDaily——

Approximate values pulled from the research — double-check before dosing.

§01Summary

Cetrorelix is a synthetic peptide that works by blocking the body's gonadotropin-releasing hormone (GnRH) receptor, which rapidly and reversibly suppresses the hormones responsible for triggering ovulation. It is primarily used in assisted reproductive technology (ART), where preventing a premature ovulation surge is critical to the success of in vitro fertilization (IVF) and intrauterine insemination (IUI) procedures.

In IVF cycles, cetrorelix reduces the number of stimulation days and the total amount of hormone medication needed compared to older GnRH agonist protocols1,6. It prevents premature LH surges in the vast majority of treated patients1,6, and significantly reduces the risk of ovarian hyperstimulation syndrome (OHSS), a potentially serious complication of ovarian stimulation3,9,17. Clinical pregnancy rates achieved with cetrorelix-based protocols are comparable to those seen with traditional long GnRH agonist regimens1,3,6,9. Beyond IVF, cetrorelix has also been investigated for use in IUI cycles, where it may improve pregnancy rates by suppressing premature LH rises10, as well as for conditions such as endometriosis and benign prostatic hyperplasia (BPH), where research is actively continuing14,16.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

Cetrorelix is a synthetic decapeptide GnRH antagonist that competitively and reversibly blocks pituitary GnRH receptors (GnRHR), a class of G protein-coupled receptors (Gq/11-coupled). Unlike GnRH agonists, which cause an initial receptor activation and subsequent receptor downregulation (requiring 2–4 weeks to achieve pituitary desensitization), cetrorelix produces immediate and dose-dependent suppression of gonadotropin secretion without an initial stimulatory flare effect. This mechanistic distinction enables a shorter treatment protocol and avoids the transient hormonal exacerbation associated with agonist initiation.

Following subcutaneous administration, cetrorelix exhibits linear pharmacokinetics with Cmax and AUC increasing proportionally with dose. Terminal half-life is substantially longer with multiple dosing (20–80 hours) compared to single dosing (5–10 hours), consistent with tissue accumulation and/or altered elimination kinetics under steady-state conditions8. Peak pharmacodynamic suppression of FSH, LH, estradiol, and progesterone occurs at 6–12 hours post-single dose administration8, providing a rapid and predictable suppressive window that directly prevents the endogenous mid-cycle LH surge responsible for premature ovulation in stimulated cycles.

The downstream endocrine effects are dose-dependent: single subcutaneous doses of 0.25, 0.50, and 1.00 mg delay ovulation by 5, 10, and 13 days respectively in healthy volunteers8, establishing a clear pharmacodynamic dose-response relationship. In IVF stimulation contexts, complete LH suppression during the follicular phase is achieved with daily 0.25 mg dosing or a single 3 mg dose1,6, while FSH-driven follicular development continues under exogenous gonadotropin support. The LH suppression induced by cetrorelix does not appear to require exogenous LH supplementation to maintain adequate follicular development or embryo outcomes in unselected patient populations, as rLH co-administration significantly elevated estradiol levels without improving delivery or implantation rates5.

Cetrorelix-based protocols are associated with more homogeneous follicular maturation at the time of hCG trigger, resulting in fewer small immature follicles compared to GnRH agonist protocols9. This follicular cohort effect may contribute mechanistically to the substantially reduced OHSS incidence observed with cetrorelix, as OHSS risk is closely linked to the number of small and intermediate follicles responding to the hCG trigger. At the level of the hypothalamic-pituitary-gonadal axis, cetrorelix preserves endogenous pituitary GnRH receptor responsiveness, enabling the use of exogenous GnRH agonists (such as triptorelin) as an alternative trigger to hCG, virtually eliminating OHSS risk in antagonist-pretreated cycles without compromising oocyte or embryo quality2.

§04Evidence & efficacy

Evidence base
363Studies
201Human
49Animal

Cetrorelix demonstrates robust, replicated efficacy for its primary indication of premature LH surge prevention in IVF/ART ovarian stimulation protocols. A single 3 mg dose achieved 100% prevention of premature LH surges (LH >10 IU/L) in one pivotal RCT6, while a multiple-dose 0.25 mg/day protocol prevented premature LH/progesterone rises in 98.4% of patients in a large phase III European RCT1. Across both protocols, fertilization rates, cleavage rates, and clinical pregnancy rates are comparable to those achieved with GnRH agonist long protocols1,6,9.

A Cochrane meta-analysis found that while antagonist protocols (including cetrorelix) are associated with modestly lower ongoing pregnancy and live-birth rates compared to the GnRH agonist long protocol (OR=0.82, 95% CI 0.69–0.98)3, cetrorelix specifically maintains comparable pregnancy rates in individual RCTs1,6,9 and in an earlier meta-analysis (OR=0.91, 95% CI 0.68–1.22)17. Cetrorelix also significantly reduces total gonadotropin consumption and stimulation duration1,6, and a fixed protocol start (day 5/6) without oral contraceptive pretreatment yields the highest ongoing pregnancy rates among antagonist protocol variations4.

In IUI cycles, cetrorelix may substantially improve clinical pregnancy rates compared to rFSH alone, with one RCT reporting 53.8% versus 30.8% (P=0.017), attributed to suppression of premature LH surges10. In PCOS patients, cetrorelix-based protocols following Diane-35 pretreatment achieve comparable clinical pregnancy outcomes to GnRH agonist long protocols with fewer injections and lower gonadotropin use19. The use of rLH supplementation during cetrorelix administration does not appear to improve delivery or implantation rates in unselected IVF patients5. Flexible low-dose cetrorelix protocols achieve equivalent pregnancy rates with approximately 30% less total antagonist use13.

For endometriosis and BPH, efficacy data from registered trials are actively emerging14,16.

§05Safety

Cetrorelix has a well-characterized safety profile established across numerous randomized controlled trials in women undergoing assisted reproduction. Its most clinically significant safety advantage is a substantial reduction in ovarian hyperstimulation syndrome (OHSS): cetrorelix-based antagonist protocols are associated with a 39% reduction in severe OHSS incidence compared to GnRH agonist long protocols (RR=0.61, 95% CI 0.42–0.89)3, and one large comparative RCT reported WHO Grade II/III OHSS rates of 1.1% with cetrorelix versus 6.5% with buserelin (p=0.03)9. Interventions to prevent OHSS such as cycle coasting and cancellation are also required significantly less frequently with cetrorelix protocols3.

When cetrorelix-based antagonist protocols are combined with GnRH agonist triggering rather than hCG triggering, OHSS risk is reduced further still — one RCT in oocyte donors reported zero OHSS cases with GnRH agonist triggering versus 9 mild and 1 severe case with hCG triggering2, a particularly relevant finding given that donors are healthy volunteers with no personal therapeutic benefit from the procedure.

Premature LH breakthrough surges, a key functional safety concern, occur rarely with cetrorelix — in approximately 1.6% of patients in one large phase III RCT1. Luteal phase progesterone concentrations and luteal phase duration are maintained following cetrorelix use in IUI cycles, suggesting no clinically meaningful impairment of corpus luteum function20. In pharmacokinetic studies involving healthy female volunteers receiving single and multiple subcutaneous doses of 0.25–1.00 mg, no specific adverse events were highlighted8. General tolerability has been rated as excellent across multiple trials6,12.

The safety profile of cetrorelix in indications beyond ART — including endometriosis and BPH — is currently being characterized through registered trials, with long-term data actively emerging14,16.

§06History

Cetrorelix was developed in the late 1980s and early 1990s as part of intensive research efforts to produce clinically viable GnRH antagonists for reproductive medicine. Early GnRH antagonists suffered from histamine-releasing properties that caused systemic allergic reactions at therapeutic doses; cetrorelix represented a significant advance in the elimination of this liability through strategic amino acid substitutions in the native GnRH decapeptide sequence. The compound was synthesized and developed by Asta Medica (later Merck Serono and Aeterna Zentaris) and entered clinical investigation in the mid-1990s.

Early pharmacokinetic and pharmacodynamic characterization was established in healthy female volunteers by the late 1990s, confirming linear kinetics and dose-dependent ovulation suppression8. Pivotal phase III randomized controlled trials conducted across Europe in the late 1990s and published in 2000 validated cetrorelix's clinical utility in IVF, demonstrating shorter stimulation protocols, reduced gonadotropin consumption, and significantly lower OHSS rates compared to established GnRH agonist regimens1,6,9. These landmark trials underpinned regulatory approval: cetrorelix (Cetrotide) received European and FDA approval in 1999–2000 for prevention of premature LH surges in women undergoing controlled ovarian stimulation.

Subsequent research through the 2000s and 2010s refined dosing protocols, explored use in special populations including PCOS19 and poor responders7, and examined applications in IUI cycles10,20. More recent research has focused on protocol optimization4,13 and investigation of non-ART indications including endometriosis14 and BPH16, with trials actively registered and ongoing.

§07References